Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU

Marc Leone, Lila Bouadma, Belaïd Bouhemad, Olivier Brissaud, Stéphane Dauger, Sébastien Gibot, Sami Hraiech, Boris Jung, Eric Kipnis, Yoann Launey, et al.

To cite this version:
Marc Leone, Lila Bouadma, Belaïd Bouhemad, Olivier Brissaud, Stéphane Dauger, et al.. Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU. Annals of Intensive Care, SpringerOpen, 2018, 8 (1), pp.104. 10.1186/s13613-018-0444-0 . hal-01913318

HAL Id: hal-01913318
https://hal.archives-ouvertes.fr/hal-01913318
Submitted on 16 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU

Marc Leone¹*, Lila Bouadma², Bélaïd Bouhemad³, Olivier Brissaud⁴, Stéphane Dauger⁵, Sébastien Gibot⁶, Sami Hraiech⁷, Boris Jung⁸, Eric Kipnis⁹, Yoann Launey¹⁰, Charles-Edouard Luyt¹¹, Dimitri Margetis¹², Fabrice Michel¹³, Djamel Mokart¹⁴, Philippe Montravers¹⁵, Antoine Monsel¹⁶, Saad Nseir¹⁷, Jérôme Pugin¹⁸, Antoine Roquilly¹⁹, Lionel Velly²⁰, Jean-Ralph Zahar²¹, Rémi Bruyère²², Gérald Chanques²³, ADARPEF and GFRUP

Abstract

Background: The French Society of Anaesthesia and Intensive Care Medicine and the French Society of Intensive Care edited guidelines focused on hospital-acquired pneumonia (HAP) in intensive care unit. The goal of 16 French-speaking experts was to produce a framework enabling an easier decision-making process for intensivists.

Results: The guidelines were related to 3 specific areas related to HAP (prevention, diagnosis and treatment) in 4 identified patient populations (COPD, neutropenia, post-operative and paediatric). The literature analysis and the formulation of the guidelines were conducted according to the Grade of Recommendation Assessment, Development and Evaluation methodology. An extensive literature research over the last 10 years was conducted based on publications indexed in PubMed™ and Cochrane™ databases.

Conclusions: HAP should be prevented by a standardised multimodal approach and the use of selective digestive decontamination in units where multidrug-resistant bacteria prevalence was below 20%. Diagnosis relies on clinical assessment and microbiological findings. Monotherapy, in the absence of risk factors for multidrug-resistant bacteria, non-fermenting Gram-negative bacilli and/or increased mortality (septic shock, organ failure), is strongly recommended. After microbiological documentation, it is recommended to reduce the spectrum and to prefer monotherapy for the antibiotic therapy of HAP, including for non-fermenting Gram-negative bacilli.

Introduction

Hospital-acquired pneumonia (HAP) is the most common infection in the intensive care unit (ICU) [1]. In the ICU, HAP is associated with a mortality rate of 20% and with increased duration of mechanical ventilation and ICU and hospital length-of-stay [2, 3]. The criteria to diagnose pneumonia are shown in Table 1 (Fig. 1).

Method

Sixteen French-speaking experts produce guidelines in three specific areas related to HAP: prevention, diagnosis and treatment as well as the specificities pertaining to different identified patient populations (COPD, neutropenia, post-operative and paediatric). The schedule of the group was defined upstream (Table 2) (Fig. 2).

The questions were formulated according to the PICO (Patient, Intervention, Comparison, Outcome) format. The formulation of the guidelines was conducted according to the GRADE methodology (Grade of Recommendation Assessment, Development and Evaluation) [4, 5]. In the absence of supporting literature, a question could be addressed by a recommendation under the form of an expert opinion (“the experts suggest that…”) (Fig. 3).

*Correspondence: Marc.LEONE@ap-hm.fr
¹ Service d’Anesthésie et de Réanimation, Aix-Marseille Université Hopital Nord, chemin des Bourrely, 13015 Marseille, France
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
These guidelines with their arguments were published in the journal Anaesthesia Critical Care and Pain Medicine [6] (Fig. 4).

First area, PREVENTION Which HAP prevention approaches decrease morbidity and mortality in ICU patients?

R1.1 We recommend using a standardised multimodal HAP prevention approach in order to decrease ICU patient morbidity (Grade 1+).

R1.1 Paediatrics We suggest using standardised multimodal approach aiming at preventing HAP in order to decrease paediatric ICU patient morbidity (Grade 2+).

R1.2 In units where multidrug-resistant bacteria prevalence is low (<20%), we suggest applying routine selective digestive decontamination using topical antiseptic administered enterally and a maximal 5-day course of systemic prophylactic antibiotic to decrease mortality (Grade 2+).

R1.3 Within a standardised multimodal HAP prevention approach, we suggest combining some of the following methods to decrease ICU patient morbidity:

- Promote the use of non-invasive ventilation to avoid tracheal intubation (mainly in post-operative digestive surgery patients and in patients with COPD),
- Favour orotracheal over nasotracheal intubation when required

### Table 1 Criteria for defining pneumonia

| Radiological signs |
|--------------------|
| Two successive chest radiographs showing new or progressive lung infiltrates |
| In the absence of medical history of underlying heart or lung disease, a single chest radiograph is enough |

And at least one of the following signs

- Body temperature > 38.3 °C without any other cause
- Leucocytes < 4000/mm³ or ≥ 12,000/mm³

And at least two of the following signs

- Purulent sputum
- Cough or dyspnoea
- Declining oxygenation or increased oxygen requirement or need for respiratory assistance

### Table 2 Guideline timeline

| Date | Event |
|------|-------|
| 5 December 2016 | Start-up meeting |
| 6 March 2017 | Vote: first round |
| 13 March 2017 | Post-vote deliberation meeting |
| 1 April 2017 | Vote: second round |
| 16 April 2017 | Amendment of two guidelines |
| 28 April 2017 | Vote of the two amended guidelines |
| 10 May 2017 | Guideline finalisation meeting |

### Protocol 1

1. Favour non-invasive ventilation (NIV) (mainly following digestive surgery and for COPD patients)

When invasive ventilation is required:

2. Apply* a selective digestive decontamination protocol with prophylactic systemic antibiotic treatment <5 days

*If the prevalence of multiresistant bacteria is low (<20%)

3. Associate some of the following methods (1st line):

- Favour the use of NIV to prevent intubation
- Limit dose and duration of sedatives and analgesics associated with mechanical ventilation
- Initiate early enteral feeding
- Regularly verify endotracheal tube cuff pressures
- Perform sub-glottic suction (1/6-8 hours) using an appropriate endotracheal tube
- Favour the orotracheal route for intubation

NB: The association of head of bed elevation <30° and/or oro-pharyngeal decontamination with 0.12 or 0.2% chlorhexidine could be proposed in association to these measures, despite low efficiency, because they do not cost much and are well tolerated.

4. Avoid using the following methods:

- Systematic early tracheotomy (apart from specific indications)
- Antulcer prophylaxis (apart from specific indications)
- Post-pyloric enteral feeding (apart from specific indications)
- Probiotics
- Systematic early changing of humidifier filters (apart from a recommendation from the manufacturer)
- Closed endotracheal suction systems
- The use of intubation tubes lined/coated or incorporating silver or antiseptics, or with an “optimised” cuff shape
- Oro-pharyngeal decontamination using povidone-iodine
- Prophylactic nebulised antibiotics
- Daily skin decontamination using antiseptics

---

**Fig. 1** Multimodal healthcare associated pneumonia prevention protocol (expert opinion)
Protocol 2

Oro-pharyngeal application (x4/ day, until tracheal extubation) of a paste or gel containing
- polymyxin E (2%)
- tobramycin (2%)
- amphotericin B (2%)
+ Administration (x4/ day, until tracheal extubation) through a nasogastric tube of 10ml of a suspension containing
- 100 mg Polymyxin E
- 80 mg Tobramycin
- 500 mg Amphotericin B
+ Intravenous administration of a prophylactic antibiotic treatment during 48 to 72 hours for patients who do not require curative antibiotic therapy
- cefazolin 1 g x 3 / d*
- In case of allergy to cephalosporins:
  - ofloxacin 200 mg x 2 / d*
  - ciprofloxacin 400 mg x 2 / d *
(*dosages in the absence of renal failure, provided for information purposes only)

Preparation for selective digestive decontamination
(provided for information purposes only)

|                       | Oral gel (jar 125 ml) | Suspension (bottles 15 ml) |
|-----------------------|-----------------------|-----------------------------|
| polymyxin E           | 4 g                   | 1 g                         |
| gentamicin            | 4 g                   | 0.8 g                       |
| amphotericin B        | 4 g                   | 5 g                         |
| sterile water         | 134 ml                | 100 ml                      |
| methylcarboxycellulose| 6 g                   |                             |
| methylparahydroxybenzoate | 0.3 g                |                             |
| propylene glycol      | 50 ml                 |                             |
| menthol alcohol       | 6 ml                  |                             |
Protocol 3

≥ 48 h
from admission to healthcare facility
or exposure to invasive ventilation (intubation)

Clinically suspected = new onset or worsening of the following:
- fever (≥ 38.3°C)
- purulent or modified sputum
- leukocytosis (≥12000/mm³) or leukopenia (≤ 4000/mm³)
- decline in oxygenation or increased oxygen-requirement
- focal abnormal lung auscultation
- sepsis or septic shock and no other source of infection

Differentials
- atelectasis
- selective intubation
- pleural effusion

Complicated forms
- lung abscesses
- empyema

New or worsening lung infiltrate(s) = radiological diagnosis

Chest radiograph(s)*

Obtain airway samples and initiate empiric treatment

Airway sampling (invasive or non) + sample culture

Positive (non-quantitative culture)
≥ sample-type threshold (quantitative culture) = microbiological diagnosis

Adapt / de-escalate treatment based on pathogen identification

Susceptibility-testing = antibiogram

Adapt / de-escalate treatment based on susceptibility

*N.B.: In case of radiographic doubt, it is possible to search for infiltrates using non-contrast thoracic computed tomography or consolidation using ultrasound.

Fig. 3 Diagnostic procedure (expert opinion)
### Protocol 4

| Nosological framework | Therapeutic class | Antimicrobials | Dosing regimen |
|-----------------------|-------------------|----------------|---------------|
| **Early pneumonia < 5 days**<br>absence of septic shock<br>absence of MDR bacteria risk factors | β-lactam, inactive against *P. aeruginosa* | amoxicillin/ clavulanic acid or 3rd gen. cephalosporin, cefotaxime | 3 to 6 g/d |
| | | In case of allergy to β-lactam : levofloxacin | 500 mg x 2/d |
| **Early pneumonia < 5 days**<br>presence of septic shock<br>absence of MDR bacteria risk factors | β-lactam, inactive against *P. aeruginosa*<br> + Aminoglycoside b or + Fluoroquinolone | amoxicillin/ clavulanic acid or 3rd gen. cephalosporin, cefotaxime<br> Example: gentamicin or Example: ofloxacin | 3 to 6 g/d or 3 to 6 g/day |
| | | In case of allergy to β-lactam : Levofloxacin + Gentamicin | 500 mg x 2/d or 8 mg/kg/d |
| **Late pneumonia ≥ 5 days**<br>or presence of other risk factors for nonfermenting Gram-negative bacilli * | β-lactam, ACTIVE against *P. aeruginosa*<br> + Aminoglycoside b or Fluoroquinolone | cefazidime or cefepime or piperacillin-tazobactam or in case of ESBL c imipenem-clastatine or meropenem + amikacin d or ciprofloxacin | 6 g/d or 4 to 6 g/d or 16 g/d or 3 g/d or 3 to 6 g/d |
| | | In case of allergy to β-lactam aztreonam + clindamycin | 30 mg/kg/d or 400 mg x 3/d or 3 to 6 g/d or 600 mg x 3 to 4/d |
| **Any presentation,**<br>presence of MRSA risk factors** | add agent active against MRSA | vancomycin or linezolid | 15 mg/kg loading followed by 30 to 40 mg/kg/d continuous or 600 mg x 2/d |

---

* Doses are given for information purposes only in patients with normal renal function and standard weight; <br> b Favour the use of aminoglycosides over fluoroquinolones to limit emergence of MDR bacteria; <br> c According to the guidelines’ criteria « Reduce de use of antibiotics in intensive care unit» ;<br> d Favour the use of amikacin over gentamicin due to enhanced efficacy against non-fermenting Gram-negative bacilli.

*Risk factors for non-fermenting Gram-negative bacilli: antibiotic therapy in the previous 90 days, prior hospital stay of more than 5 days, renal replacement therapy requirement during pneumonia, septic shock, acute respiratory distress syndrome.

**Methicillin-resistant *Staphylococcus aureus* (MRSA) risk factors: high local prevalence of MRSA, recent colonisation by MRSA, chronic skin lesions, chronic renal replacement therapy.
• Limit dose and duration of sedatives and analgesics (promote their use guided by sedation/pain/agitation scales, and/or daily interruptions),
• Initiate early enteral feeding (within the first 48 h of ICU admission),
• Regularly verify endotracheal tube cuff pressure,
• Perform sub-glottic suction (every 6 to 8 h) using an appropriate endotracheal tube (Grade 2+).

R1.4 Within a standardised multimodal HAP prevention approach, we suggest not using the following methods to decrease ICU patient morbidity:

• Systematic early (< day 7) tracheotomy (except for specific indications),
• Anti-ulcer prophylaxis (except for specific indications),
• Post-pyloric enteral feeding (except for specific indications),
• Administration of probiotics and/or synbiotics,
• Early systematic change of the humidifier filter (except for specific manufacturer recommendations)
• Use of closed suctioning systems for endotracheal secretions,
• Use of antiseptic-coated intubation tubes or with tubes an “optimised” cuff shape,
• Selective oropharyngeal decontamination (SOD) with povidone-iodine,
• Use of prophylactic nebulised antibiotics,
• Daily skin decontamination using antiseptics (Grade 2−).

R1.5 In weaning of COPD patients from ventilation, we suggest using non-invasive ventilation to reduce length of invasive mechanical ventilation, incidence of HAP, morbidity and mortality (Grade 2+).

Second area, DIAGNOSIS What methods to diagnose HAP should be used to decrease ICU patient morbidity and mortality?

R2.1 We suggest not using the clinical scores (CPIS, modified CPIS) for diagnosing HAP (Grade 2−).

R2.2 We suggest collecting microbiological airway samples, regardless of type, before initiation of any change in antibiotic therapy (Grade 2+).

R2.3 We suggest not measuring plasma or alveolar levels of procalcitonin or soluble TREM-1 to diagnose HAP (Grade 2−).

Third area, TREATMENT What therapeutic options for HAP should be used to decrease ICU patient morbidity and mortality?

R3.1 We suggest immediately collecting samples and initiating antibiotic treatment taking into consideration risk factors for multidrug-resistant bacteria in patients with suspected HAP and haemodynamic or respiratory compromise (shock or acute respiratory distress syndrome) or frailty such as immunosuppression [95–100] (Grade 2+).

R3.2 We recommend treating HAP in mechanically ventilated immunocompetent patients empirically by a monotherapy, in the absence of risk factors for multidrug-resistant bacteria, non-fermenting Gram-negative bacilli and/or increased mortality (septic shock, organ failure) [101–113] (Grade 1+).

R3.3 The experts suggest not systematically directing empiric antibiotic therapy against methicillin-resistant Staphylococcus aureus in the treatment of HAP [114–119] (Experts Opinion).

R3.4 We suggest reducing the spectrum and preferring monotherapy for the antibiotic therapy of HAP after microbiological documentation, including for non-fermenting Gram-negative bacilli [114,115,120–128] (Grade 2+).

R3.5 We recommend not prolonging for more than 7 days the antibiotic treatment for HAP, including for non-fermenting Gram-negative bacilli, apart from specific situations (immunosuppression, empyema, necrotising or abscessed pneumonia) [129–135] (Grade 1−).

R3.6 We suggest administering nebulised colimycin (sodium colistiméthate) and/or aminoglycosides in documented HAP due multidrug-resistant Gram-negative bacilli documented pneumonia established as sensitive to colimycin and/or aminoglycoside, when no other antibiotics can be used (based on the results of susceptibility testing) [136–152] (Grade 2+).

R3.7 We recommend not administering statins as adjuvant treatment for HAP [153–161] (Grade 1−).

Authors’ contributions
Marc Leone and Lila Bouadma proposed the elaboration of this recommendation and manuscript in agreement with the “Société Française d’Anesthésie et de Réanimation” and the “Société de Réanimation de Langue Française”
Gérald Chanques, Rémi Bruyère and Lionel Velly wrote the methodology section and gave the final version with the final presentation. Antoine Roquilly, Charles-Edouard Luyt and Jean-Ralph Zahar contributed to elaborate recommendations and write the rationale of question 1 (prevention). Sébastien Gibot, Bélaïd Bouhemad, Jérôme Pugin and Eric Kipnis contributed to elaborate recommendations and to write the rationale of question 2 (diagnosis). Antoine Monsel, Sami Hraiech and Boris Jung contributed to elaborate recommendations and to write the rationale of question 3 (treatment). Djamel Mokart contributed to elaborate recommendations and to write the rationale about neutropenic patients. Saad Nseir contributed to elaborate recommendations and to write the rationale about COPD patients. Olivier Brissaud, Stéphane Dauger and Fabrice Michel contributed to elaborate paediatrics recommendations and to write the rationale of paediatrics issues. Antoine Launey and Dimitri Margetis provide references. Marc Leone and Lila Bouadma drafted the manuscript. All authors read and approved the final manuscript.

Author details
1 Service d’Anesthésie et Réanimation, Aix-Marseille Université-Hôpital Nord, chemin des Bourrely, 13015 Marseille, France. 2 Service de Réanimation Médicale, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, France. 3 Service d’Anesthésie et Réanimation, Centre Hospitalier Universitaire de Dijon, Paris, France. 4 Unité de Réanimation Pédiatrique, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. 5 Service de Réanimation Pédiatrique, Hôpital Universitaire Robert-Debre, Paris, France. 6 Service de Réanimation Médicale, CHU de Nancy, Vandoeuvre-les-Nancy, France. 7 Service de Réanimation des Détresses Respiratoires et des Infections Sévères, Aix-Marseille Université, Hôpital Nord, Marseille, France. 8 Service d’Anesthésie et Réanimation, CHU de Montpellier, Montpellier, France. 9 Service d’Anesthésie et Réanimation, CHU de Lille, Lille, France. 10 Service d’Anesthésie et Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France. 11 Institut de Cardiologie, Service de Réanimation Médicale, Hôpital Universitaire Pitié Salpetrière, AP-HP, Paris, France. 12 Service de Réanimation Médicale - Hôpital Saint-Antoine, Paris, France. 13 Service d’Anesthésie et Réanimation, Hôpital La Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France. 14 Service de Réanimation, Institut Paoli-Calmettes, Marseille, France. 15 Département d’Anesthésie Réanimation, CHU Bichat - Claude-Bernard, AP-HP, Paris, France. 16 Département d’Anesthésie et Réanimation, Université Pierre et Marie Curie, Paris, France. 17 Centre de Soins Intensifs, Service de Réanimation, Centre Hospitalier Regional Universitaire de Lille, Lille, France. 18 Service de Soins Intensifs, Hopitaux Universitaires de Genève, Genève, Switzerland. 19 Service d’Anesthésie et Réanimation, CHU de Nantes, Nantes, France. 20 Département d’Anesthésie et Réanimation, Hôpital de la Timone, AP-HM, Paris, France. 21 Département de Microbiologie Clinique, Hôpital Avicenne, AP-HP, Paris, France. 22 Service de Réanimation, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, France. 23 Département d’Anesthésie Réanimation, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, France.

Acknowledgements
Guidelines reviewed and endorsed by the SFAR (29/06/2017) and SRLF boards (08/06/2017).

Competing interests
The authors declare the following competing interests: Sébastien Gibot: Inotrem S.A, Eric Kipnis: Astellas, LFPh, Pfizer, Marc Leone: MSD, Basilea, Charles-Edouard Luyt: Bayer Healthcare, Thermo Fisher BRAHMS, MSD, Biomerieux, Djamel Mokart: Gilead, Basilea, MSD, Philippe Montravers: Pfizer, MSD, Basilea, AstraZeneca; Bayer; Menari; Parexel, Cubist, Saad Nseir: Medtronic; Cielmedical; Bayer, Jérôme Pugin: Bayer; part of the scientific committee for the Amikacin Inhalne study. Jean-Ralph Zahar. MSD; Bard. The remaining authors declare no competing interests.

Availability of data and materials
Not applicable.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
This work was financially supported by the Société Française d’Anesthésie et de Réanimation (SFAR) and the Société de Réanimation de Langue Française (SRLF).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 11 August 2018 Accepted: 8 October 2018
Published online: 03 November 2018

References
1. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2016;36:1999.
2. Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2017;46:322.
3. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klairn B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scanapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–71.
4. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
6. Leone M, Boudadma L, Bouhemad B, Brissaud O, Dauger S, Gibot S, Hraiech S, Jung B, Kipnis E, Launey Y, Luyt CE, Margetis D, Michel F, Mokart D, Montravers P, Monsel A, Nseir S, Pugin J, Roquilly A, Velly L, Zahar JR, Bruyère R, Chanques G. Hospital-acquired pneumonia in ICU. Anaesth Crit Care Pain Med. 2018;37(1):83–98.